about
A quantitative chemical proteomics approach to profile the specific cellular targets of andrographolide, a promising anticancer agent that suppresses tumor metastasisModeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs.Trisubstituted Sulfonamides: a New Chemotype for Development of Potent and Selective CB2 Receptor Inverse Agonists.Small-molecule inhibitors targeting INK4 protein p18(INK4C) enhance ex vivo expansion of haematopoietic stem cells.Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5.Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.Multi-Functional Diarylurea Small Molecule Inhibitors of TRPV1 with Therapeutic Potential for Neuroinflammation.LiCABEDS II. Modeling of ligand selectivity for G-protein-coupled cannabinoid receptorsp62/SQSTM1/Sequestosome-1 is an N-recognin of the N-end rule pathway which modulates autophagosome biogenesis.Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activitiesDiscovery of Novel Ligands for TNF-α and TNF Receptor-1 through Structure-Based Virtual Screening and Biological Assay.Synthesis, Biological Evaluation, and Autophagy Mechanism of 12N-Substituted Sophoridinamines as Novel Anticancer Agents.Targeted inhibition of the type 2 cannabinoid receptor is a novel approach to reduce renal fibrosisA novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapyDiscovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening
P50
Q23005474-EED67DD5-C300-45FB-A40C-E2B0B5199E74Q34222925-13FE1429-F194-4ED6-98C9-739806F1203DQ35147183-D535D291-3E1D-403A-A7F7-5B02408F8995Q35867771-42904C2D-D210-4F43-A6EC-63C4696032ADQ36385771-14D02925-0D6B-4A34-B673-32912D3764ADQ36540462-D4393815-436E-4E18-B23E-AC7959ED92FAQ37676906-E6F151D8-C4BD-4866-8E75-334ED6812873Q38540618-A8612C9A-DBED-482C-BA5F-E589C1819B48Q41107844-BB98155F-A689-47CB-8B43-D365986257ECQ41895092-EF14C331-0765-4F16-9234-80A1956E6C94Q48258862-3BF6034F-D6E8-49F8-84EB-AB623F507A0DQ50319360-70A803E2-2790-4FC6-B17B-9009BF7BB667Q90857576-FCD05C52-3518-4E2E-B267-7431981BE1BEQ92123713-9BA92E9F-23F8-4D7B-9B35-6D566FACD75EQ94647499-D081CD6E-F662-4320-9066-556FD8EC29C0
P50
description
researcher (ORCID 0000-0002-2613-941X)
@en
wetenschapper
@nl
name
Peng Yang
@en
Peng Yang
@nl
type
label
Peng Yang
@en
Peng Yang
@nl
prefLabel
Peng Yang
@en
Peng Yang
@nl
P31
P496
0000-0002-2613-941X